EXELIXIS INC
Acción · US30161Q1040 · EXEL · 936718 (XNAS)
43,00 USD
06.06.2025 23:58
Cotizaciones actuales de EXELIXIS INC
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
EXEL
|
USD
|
06.06.2025 23:58
|
43,00 USD
| 42,37 USD
+1,49 %
|
![]() London |
0IJO.L
|
USD
|
06.06.2025 15:07
|
42,86 USD
| 42,37 USD
+1,16 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | -0,58 % | 16,66 % | 12,54 % | 20,04 % | 95,90 % | 92,22 % |
Perfil de la empresa para EXELIXIS INC Acción
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Fondos invertidos
Los siguientes fondos han invertido en: EXELIXIS INC invertido:
Fondo | Vol. en millones 210,29 | Porcentaje (%) 0,49 % |
Datos de la empresa
Nombre EXELIXIS INC
Empresa Exelixis, Inc.
Símbolo EXEL
Sitio web
https://www.exelixis.com
Mercado principal
NASDAQ

WKN 936718
ISIN US30161Q1040
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Michael M. Morrissey Ph.D.
Capitalización de mercado 9 Mrd.
País Estados Unidos de América
Moneda USD
Empleados 1,3 T
Dirección 1851 Harbor Bay Parkway, 94502 Alameda
Fecha de OPV 2007-10-01
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | EX9.F |
London | 0IJO.L |
NASDAQ | EXEL |
XETRA | EX9.DE |
Otras acciones
Los inversores que tienen EXELIXIS INC también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.